# To Document the Burden of Illness on the Quality of Life and the Impact on Healthcare Utilization in (Beta) β-thalassemia Subjects Who Are Transfusion Dependent (TD) and Non-transfusion Dependent (NTD) Receiving Standard of Care

> **NCT02626689** · — · COMPLETED · sponsor: **Celgene** · enrollment: 100 (actual)

## Conditions studied

- Beta-Thalassemia

## Interventions

- **OTHER:** Quality of Life (QOL) questionnaires
- **OTHER:** Healthcare Resource Utilization

## Key facts

- **NCT ID:** NCT02626689
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-01
- **Primary completion:** 2017-01-03
- **Final completion:** 2017-01-03
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02626689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02626689, "To Document the Burden of Illness on the Quality of Life and the Impact on Healthcare Utilization in (Beta) β-thalassemia Subjects Who Are Transfusion Dependent (TD) and Non-transfusion Dependent (NTD) Receiving Standard of Care". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02626689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*